Analysts at Mizuho Securities Reiterated their Buy rating for Heron Therapeutics (HRTX). The TP Given is $41.0000; 2 Bullish Analysts Covering Tanger Factory Outlet Centers, Inc. (SKT)

Tanger Factory Outlet Centers, Inc. (NYSE:SKT) Logo

Equity analysts at Mizuho Securities have $41.0000 target price per share on Heron Therapeutics (NASDAQ:HRTX). Mizuho Securities’s target price per share indicates a potential upside of 2.63% from the company’s previous stock close. The rating was disclosed to clients in a note on Thursday, 21 June.

Among 10 analysts covering Tanger Factory Outlet Centers (NYSE:SKT), 2 have Buy rating, 3 Sell and 5 Hold. Therefore 20% are positive. Tanger Factory Outlet Centers had 39 analyst reports since July 21, 2015 according to SRatingsIntel. As per Thursday, February 15, the company rating was downgraded by Evercore. As per Thursday, October 29, the company rating was downgraded by Hilliard Lyons. The stock of Tanger Factory Outlet Centers, Inc. (NYSE:SKT) earned “” rating by KeyBanc Capital Markets on Friday, August 7. KeyBanc Capital Markets maintained the shares of SKT in report on Monday, October 23 with “Hold” rating. Jefferies downgraded the shares of SKT in report on Friday, June 16 to “Hold” rating. As per Wednesday, January 4, the company rating was upgraded by Jefferies. The stock of Tanger Factory Outlet Centers, Inc. (NYSE:SKT) earned “In-Line” rating by Evercore on Monday, August 14. Bank of America downgraded Tanger Factory Outlet Centers, Inc. (NYSE:SKT) on Friday, June 23 to “Underperform” rating. The firm has “Buy” rating given on Tuesday, December 8 by Goldman Sachs. The rating was maintained by Jefferies with “Hold” on Monday, October 23. See Tanger Factory Outlet Centers, Inc. (NYSE:SKT) latest ratings:

02/05/2018 Broker: KeyBanc Capital Markets Old Rating: Sector Weight New Rating: Underweight Downgrade
15/02/2018 Broker: Evercore Old Rating: In-Line New Rating: Underperform Downgrade

The stock increased 30.13% or $9.25 during the last trading session, reaching $39.95. About 11.24M shares traded or 774.01% up from the average. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 111.78% since June 22, 2017 and is uptrending. It has outperformed by 99.21% the S&P500. Some Historical HRTX News: 24/05/2018 – Recro Pharma: FDA Is Unable to Approve the New Drug Application for IV Meloxicam in Its Current Form; 26/03/2018 – Heron Therapeutics Presenting at Conference Tomorrow; 10/05/2018 – HERON THERAPEUTICS INC – REAFFIRMS FULL-YEAR 2018 CINV FRANCHISE NET PRODUCT SALES GUIDANCE OF $60 MLN TO $70 MLN; 19/03/2018 – HERON: HTX-011 ACHIEVED ALL PRIMARY & KEY SECONDARY ENDPOINTS; 28/03/2018 – Heron Therapeutics Announces Proposed Public Offering of Common Stk; 08/05/2018 – Heron’s G2 Lens Delivers Strong Metallurgical Results; 11/04/2018 – MYLAN ACQUIRED RIGHTS FROM PRAYOG LABS ON MELOXICAM; 04/04/2018 – Work Capital Announces New Partnership with the Heron Foundation; 10/05/2018 – Heron Therapeutics 1Q Loss/Shr 81c; 30/05/2018 – SEDOR PHARMACEUTICALS SAYS CO HAS GRANTED LOS ALTOS AN EXCLUSIVE LICENSE FOR CAPTISOL-ENABLED MELOXICAM FOR THE PEOPLE’S REPUBLIC OF CHINA

More notable recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Streetinsider.com which released: “Pre-Open Movers 06/21: (CASI) (HRTX) (DRI) (KR) Higher; (VERI) (LMNR) (AOBC) Lower (more…)” on June 21, 2018, also Nasdaq.com with their article: “Mid-Day Market Update: Dow Down Over 150 Points; CASI Pharmaceuticals Shares Spike Higher” published on June 21, 2018, Nasdaq.com published: “Why Stitch Fix, Barnes & Noble Education, and Heron Therapeutics Jumped Today” on June 21, 2018. More interesting news about Heron Therapeutics, Inc. (NASDAQ:HRTX) were released by: Streetinsider.com and their article: “Heron Therapeutics (HRTX) Says HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy …” published on June 21, 2018 as well as Schaeffersresearch.com‘s news article titled: “2 Stocks Making Massive Moves on Supreme Court Ruling” with publication date: June 21, 2018.

Analysts await Heron Therapeutics, Inc. (NASDAQ:HRTX) to report earnings on August, 8. They expect $-0.68 EPS, up 15.00% or $0.12 from last year’s $-0.8 per share. After $-0.81 actual EPS reported by Heron Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -16.05% EPS growth.

Among 15 analysts covering Heron Therapeutics (NASDAQ:HRTX), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics has $58 highest and $22 lowest target. $41.57’s average target is 4.06% above currents $39.95 stock price. Heron Therapeutics had 44 analyst reports since August 3, 2015 according to SRatingsIntel. On Tuesday, February 27 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The rating was maintained by Cowen & Co with “Buy” on Friday, May 26. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Jefferies on Tuesday, August 15. The rating was maintained by Cowen & Co with “Buy” on Wednesday, December 6. Mizuho maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Tuesday, November 7. Mizuho has “Buy” rating and $28.0 target. The rating was maintained by Cantor Fitzgerald with “Buy” on Sunday, April 22. The company was maintained on Wednesday, September 23 by Jefferies. The firm has “Outperform” rating given on Wednesday, September 23 by Leerink Swann. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Aegis Capital on Thursday, June 1. The firm earned “Buy” rating on Tuesday, September 26 by Mizuho.

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company has market cap of $2.87 billion. The companyÂ’s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It currently has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.

Since February 15, 2018, it had 0 buys, and 5 insider sales for $538,869 activity. 4,400 shares were sold by Worsham Charles Allen, worth $92,928. Shares for $254,274 were sold by McDonough Thomas E.. 5,800 shares valued at $132,791 were sold by SUMMERELL VIRGINIA R on Monday, February 26. WARREN CARRIE A sold $49,026 worth of stock or 2,357 shares.

The stock increased 0.95% or $0.22 during the last trading session, reaching $23.26. About 960,027 shares traded. Tanger Factory Outlet Centers, Inc. (NYSE:SKT) has declined 20.20% since June 22, 2017 and is downtrending. It has underperformed by 32.77% the S&P500. Some Historical SKT News: 18/05/2018 – Tanger Elects Directors and Officers; 12/04/2018 – TANGER INCREASES DIV FOR 25TH CONSECUTIVE YR CONTINUES SHR; 01/05/2018 – Tanger Factory Outlet Cuts FY View To EPS 95c-EPS $1.01; 08/03/2018 Tanger Outlets Invites Shoppers To “Feel The Deal” This Spring With TangerSTYLE; 01/05/2018 – TANGER 1Q AFFO/SHR 60C, EST. 59C; 12/04/2018 – Tanger Factory Outlet Raises Dividend to $1.40 Vs. $1.37; 15/05/2018 – Millennium Management Buys New 2.2% Position in Tanger; 01/05/2018 – Tanger Factory Outlet 1Q Rev $123.5M; 30/03/2018 – Columbus Bus 1st: Exclusive: Developer teeing up new 225-home development near Tanger Outlets; 23/03/2018 – Tanger Conference Call Scheduled By Stuart Frankel for Mar. 29

More notable recent Tanger Factory Outlet Centers, Inc. (NYSE:SKT) news were published by: Seekingalpha.com which released: “Tanger Factory Outlet Centers: A Dividend Aristocrat On Sale” on June 12, 2018, also Fool.com with their article: “3 Stocks That Are Absurdly Cheap Right Now” published on June 19, 2018, Globenewswire.com published: “Factors of Influence in 2018, Key Indicators and Opportunity within Companhia Brasileira de Distribuicao, SiteOne …” on June 15, 2018. More interesting news about Tanger Factory Outlet Centers, Inc. (NYSE:SKT) were released by: Bizjournals.com and their article: “Bob Parsons’ company buys Westgate Entertainment District for $133M” published on June 12, 2018 as well as Seekingalpha.com‘s news article titled: “5%+ Dividend Yield Portfolio: Contrarian Bets Pay Off (May 2018 Review)” with publication date: June 04, 2018.

Tanger Factory Outlet Centers, Inc. (NYSE:SKT) Institutional Positions Chart